Literature DB >> 24497782

How best to describe the risk of meningococcal B infection?

Manish Sadarangani1, Julie A Bettinger2, David W Scheifele2.   

Abstract

Entities:  

Year:  2013        PMID： 24497782      PMCID： PMC3907351          DOI： 10.1093/pch/18.10.543

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


× No keyword cloud information.
  5 in total

1.  Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

Authors:  Nicoletta Gossger; Matthew D Snape; Ly-Mee Yu; Adam Finn; Gianni Bona; Susanna Esposito; Nicola Principi; Javier Diez-Domingo; Etienne Sokal; Birgitta Becker; Dorothee Kieninger; Roman Prymula; Peter Dull; Ellen Ypma; Daniela Toneatto; Alan Kimura; Andrew J Pollard
Journal:  JAMA       Date:  2012-02-08       Impact factor: 56.272

Review 2.  The changing and dynamic epidemiology of meningococcal disease.

Authors:  Scott A Halperin; Julie A Bettinger; Brian Greenwood; Lee H Harrison; Jane Jelfs; Shamez N Ladhani; Peter McIntyre; Mary E Ramsay; Marco A P Sáfadi
Journal:  Vaccine       Date:  2011-12-15       Impact factor: 3.641

3.  Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.

Authors:  Timo Vesikari; Susanna Esposito; Roman Prymula; Ellen Ypma; Igor Kohl; Daniela Toneatto; Peter Dull; Alan Kimura
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321

4.  Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).

Authors:  Julie A Bettinger; David W Scheifele; Scott A Halperin; Wendy Vaudry; Jamie Findlow; Ray Borrow; Duccio Medini; Raymond Tsang
Journal:  Vaccine       Date:  2013-04-12       Impact factor: 3.641

5.  The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.

Authors:  Julie A Bettinger; David W Scheifele; Nicole Le Saux; Scott A Halperin; Wendy Vaudry; Raymond Tsang
Journal:  Pediatr Infect Dis J       Date:  2009-03       Impact factor: 2.129
  5 in total
  2 in total

Review 1.  Meningococcal vaccination in pregnancy.

Authors:  Bahaa Abu Raya; Manish Sadarangani
Journal:  Hum Vaccin Immunother       Date:  2018-03-21       Impact factor: 3.452

2.  The role of pediatricians as key stakeholders in influencing immunization policy decisions for the introduction of meningitis B vaccine in Canada: The Ontario perspective.

Authors:  Hirotaka Yamashiro; Nora Cutcliffe; Simon Dobson; David Fisman; Ronald Gold
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Jul-Aug       Impact factor: 2.471
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.